Cost –Effectiveness of Obinutuzumab As Frontline Treatment For Unfit Patients With Chronic Lymphocytic Leukemia In Republic of Macedonia

Abstract

Authors

A Kapedanovska Nestorovska Z Sterjev Z Naumovska A Grozdanova A Dimovski L Suturkova